Abstract:
An assay device processing instrument comprises a plurality of processing modules. A transport system transports an assay device to each processing module, the transport system being adapted to transfer the assay device from the transport system to the module to enable the transport system to transport another assay device while the first is processed by the processing module. A control system controls operation of the transport system such that each assay device is transferred between the modules in a predetermined sequence, and such that a number of assay devices can be processed in different modules simultaneously.
Abstract:
Novel haptens, which can be conjugated to form immunogens, are of formula I, II or III wherein R is a divalent alkyl, cycloalkyl or aryl group having 1 to 10 carbon atoms, and X is a functional group.
Abstract:
First and second reactants that give a signal when mixed in the presence of an analyte in a liquid sample, are separately contained in sol-gels that release the reactants in the presence of the liquid. For example, when the first and second reactants respectively comprise an oxidant and a reductant, and the reaction provides a detectable signal, the system can be used to detect the presence of contaminants in a water sample. The sol-gel may be obtained by reaction of water with, per part by volume thereof, at least 2 parts of a metal alkoxide, and drying the resultant gel.
Abstract:
A method of monitoring the properties of a biological or chemical sample. The method includes carrying out a plurality of different tests on the sample to generate corresponding test data; optionally carrying out a preliminary processing of the test data to generate partially processed data; storing the test data and/or partially processed data; causing a processing system to analyze a user-defined selection of the test data or partially processed data to generate result data relating to one or more properties of the sample; and subsequent to the previous step, receiving a second user defined selection of the test data or partially processed data, different from the first selection, and causing the processing system to analyze the second user-defined selection of the test data or partially processed data to generate second result data relating to one or more properties of the sample different from the properties corresponding to the first user-defined selection.
Abstract:
An assay device incubator comprises a housing (46) defining a region within which at least one assay device is located in use, the housing defining laterally opposed sidewalls (48, 50) of at least one bay (33) in which an assay device can be located. The housing (46) includes one or more guides (49, 51) for supporting the assay device and enabling the assay device to undergo to and fro movement therealong. A vibration system (40, 60) is coupled to the at least one tray in use for vibrating the tray to and fro along the or each guide. A heating system (70) heats the region within the housing.
Abstract:
An assay for measuring the amount of a first analyte in a sample, comprises the steps of: (i) contacting the sample with a device that comprises one or more first reaction sites which comprise a first ligand having affinity for the first analyte, and a series of second reaction sites each comprising different known concentrations of an immobilized second analyte; (ii) removing any unbound first analyte; (iii) contacting the device with a second ligand that is detectably labelled and which has affinity for the first analyte, and a third ligand that is detectably labelled and which has affinity for the second analyte; (iv) removing any unbound second and third ligands; and (v) measuring the amount of second and third ligands, wherein measurement of the third ligand is used to establish a calibration curve, used to determine the amount of first analyte present in sample.
Abstract:
A method for the detection of the presence of or the risk of cancer in a patient, comprising, with reference to a normal control, the step of: (i) detecting the expression level of a gene characterised by any of the nucleotide sequences identified herein as SEQ ID No. 1 to SEQ ID No. 10, in a sample isolated from a patient, wherein an increased expression level of the gene characterised by any of SEQ ID Nos. 1 to 6 and 10, or a decreased expression level of the gene characterised by any of SEQ ID Nos. 7 to 9, indicates the presence of or the risk of cancer in the patient from whom the sample was isolated.
Abstract translation:一种检测患者癌症存在或癌症风险的方法,包括参照正常对照的步骤:(i)检测以本文所鉴定的任何核苷酸序列为特征的基因的表达水平 作为SEQ ID No.1〜SEQ ID No.10所示的样品,分离自患者的样品,其中以SEQ ID NO:1至6和10中任一个为特征的基因的表达水平提高,或者表达水平降低 以SEQ ID NO:7至9中任一项为特征的基因表示在分离样品的患者中存在癌症的风险或癌症的风险。
Abstract:
A method for stabilizing an enzyme during freezing, wherein the enzyme is in a zwitterionic buffer solution. The zwitterionic buffer is able to maintain the activity of the enzyme during freezing and thawing.
Abstract:
Liquid dispensing apparatus comprises a support member which supports a movably mounted dispensing member. The support member is movable between first and second positions. A single drive system causes the dispensing member to move relative to the support member to a number of dispense positions while the support member is in its first position and causes the support member to move to the second position.
Abstract:
The invention provides a hapten, an immunogen comprising the hapten coupled to an antigenicity-conferring carrier material, a conjugate comprising the hapten coupled to a labelling agent, as well as, antibodies raised against the aforementioned immunogen and capable of binding with MDMA.